62 years of Hemofarm’s business leadership

Hemofarm has continued its growth journey also in 2022, ending the year with exceptional business results, as shared at a cocktail party hosted by the regional pharmaceutical industry leader for friends, business partners and associates. Hemofarm has celebrated 62 years of successful operation, emphasizing that good health of everyone is the core mission of the company and its greatest asset.

The biggest success in 2022 is related to successful operation in an extremely demanding environment, in which Hemofarm managed to deliver all necessary products to all markets where STADA Group operates, in the required quantity and the inherent quality. Since 2006, STADA Group has invested more than 400 million EUR in Hemofarm.

‘Focusing on growth, innovations, and operational excellence, we keep on developing Hemofarm as a modern and responsible company. Following the roadmap of sustainable development, we continue along a not so well-trodden and simple path, which is nevertheless our absolute priority. We will keep on aspiring to contribute to the sustainable development of the entire society through Hemofarm’s progress and development. Business-wise, we have continued pursuing our ascending trajectory. We are finishing this year with 306 million of produced packs, accounting for a 6.8% year-on-year growth. As one of the biggest German investors, we have continued with the investments. In 2022, around 25 million EUR have been invested in strategic projects within Hemofarm Group. Our portfolio has kept on growing during 2022, and most importantly, we are the local and regional market leader in sustainable development and the most determined fighter for people's health’, said Dr Ronald Seeliger, CEO of Hemofarm, adding that Hemofarm has preserved the leadership position in both the market of Serbia, and Bosnia and Herzegovina.

According to him, Hemofarm is not only the leader in pharmaceutical industry, but also a pioneer of sustainable, smart, and responsible business in this region. The 10th jubilee Sustainable Development Report has also been published this year. Holding over 70% of total exports of pharmaceuticals from the country, Vršac-based company is simultaneously the major Serbian exporter of medicines. It operates on four continents and comprises a team of about 4000 employees. Hemofarm is present on almost 40 markets all around the world and it is one of the top pharmaceutical manufacturers in this region.

‘In addition to all successes, we are particularly proud of Hemofarm Foundation which will celebrate its 30th anniversary next year. Its perseverance in the fight for people’s health is the proof that commitment and faith in wellbeing of everyone can change the world and make a better place for all of us to live in‘, Seeliger pointed out on this occasion.